Sopharma Trading, being a wholesaler and retailer of pharmaceuticals, OTC products and cosmetics, is part of the companies at the forefront of the fight against COVID-19.
Pharma wholesaler Sopharma Trading’s (SO5 BU) consolidated revenues accelerated 6.6% y/y to BGN 465.6m, net profit margin shrank on increased costs in H1’19, according to latest consolidated financials published by the Company.
Sopharma Trading boosted its standalone revenue by 8.2% y/y to BGN 352m and expanded bottom line by 13% y/y to BGN 8.1m in H1 2018, according to the Company’s interim financial statements. The top line expansion is a result of increase in all revenue streams of the Company.
Pharmaceuticals wholesaler Sopharma Trading expanded its standalone top line by 10.4% to BGN 181.7m in Q1’18 on higher sales in all segments, according to the Company’s financial statements for Q1’18.
Leading generic pharmaceuticals producer Sopharma proposed a BGN 0.11 dividend per share (DPS), the Company disclosed in a filing to the Trade Registry. This comes very short of ELANA Trading Research team BGN 0.12 DPS estimate.
The biggest vertically integrated human health pharmaceutical group in Bulgaria Sopharma booked record performance in 2017 with the top line hitting BGN 1bn and best EBITDA ever on strong organic and M&A driven growth. Individual bottom line margins healthy above historical and peer averages at 20%+ as cost and group optimization kicked in.